Michael S. Brown - 06 Jan 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Michael S. Brown
Issuer symbol
REGN
Transactions as of
06 Jan 2023
Net transactions value
-$697,289
Form type
4
Filing time
10 Jan 2023, 15:03:48 UTC
Previous filing
05 Jan 2023
Next filing
30 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $1,596,431 +3,070 +246% $520.01 4,317 06 Jan 2023 Direct F1
transaction REGN Common Stock Sale $2,293,720 -3,070 -71% $747.14 1,247 06 Jan 2023 Direct F1, F2
holding REGN Common Stock 5,000 06 Jan 2023 by SLAT F3
holding REGN Common Stock 6,662 06 Jan 2023 by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -3,070 -33% $0.000000 6,142 06 Jan 2023 Common Stock 3,070 $520.01 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 Represents volume-weighted average price of sales of 3,070 shares of Company stock on January 6, 2023 at prices ranging from $747.00 to $747.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 6, 2023 at each separate price.
F3 These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4 The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.